Nanoparticle therapeutics: an emerging treatment modality for cancer (Q29615628)

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=18758474

30 April 2017

0 references

Davis ME

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=18758474

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=18758474

30 April 2017

Chen ZG

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=18758474

30 April 2017

Shin DM

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=18758474

30 April 2017

language of work or name

1 reference

30 April 2017

publication date

September 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=18758474

Nature Reviews Drug Discovery

30 April 2017

published in

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=18758474

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=18758474

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=18758474

30 April 2017

page(s)

771-82

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=18758474

Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers

30 April 2017

cites work

1 reference

Effect of particle size and charge on the disposition of lipid carriers after intratumoral injection into tissue-isolated tumors

31 March 2020

1 reference

Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma

31 March 2020

1 reference

Surface properties, more than size, limiting convective distribution of virus-sized particles and viruses in the central nervous system

31 March 2020

1 reference

Transferrin receptors in human tissues: their distribution and possible clinical relevance

31 March 2020

1 reference

Antibody Targeting of Long-Circulating Lipidic Nanoparticles Does Not Increase Tumor Localization but Does Increase Internalization in Animal Models

31 March 2020

1 reference

Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging

31 March 2020

1 reference

A nanoparticle-based model delivery system to guide the rational design of gene delivery to the liver. 2. In vitro and in vivo uptake results

31 March 2020

1 reference

Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles

31 March 2020

1 reference

Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors

31 March 2020

1 reference

The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform.

31 March 2020

1 reference

Multivalent effects of RGD peptides obtained by nanoparticle display

31 March 2020

1 reference

Selective tumor cell targeting using low-affinity, multivalent interactions

31 March 2020

1 reference

Camptothecins and Topoisomerase I; A Foot in the Door. Targeting the Genome Beyond Topoisomerase I with Camptothecins and Novel Anticancer Drugs; Importance of DNA Replication, Repair and Cell Cycle Checkpoints

31 March 2020

1 reference

Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging

31 March 2020

1 reference

Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing

31 March 2020

1 reference

Liposomal, nanoparticle, and conjugated formulations of anticancer agents

31 March 2020

1 reference

Cardiac safety of liposomal anthracyclines

31 March 2020

1 reference

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

31 March 2020

1 reference

A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules

31 March 2020

1 reference

Functionalized micellar systems for cancer targeted drug delivery

31 March 2020

1 reference

Resolving the nanoparticles paradox

31 March 2020

1 reference

Pegylated liposomal doxorubicin and immunomodulatory drug combinations in multiple myeloma: rationale and clinical experience.

31 March 2020

1 reference

Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).

31 March 2020

1 reference

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

31 March 2020

1 reference

Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy

31 March 2020

1 reference

Effect of pegylation on pharmaceuticals

31 March 2020

1 reference

Pegaspargase: a review of clinical studies

31 March 2020

1 reference

The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta).

31 March 2020

1 reference

Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications

31 March 2020

1 reference

Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study.

31 March 2020

1 reference

Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer

31 March 2020

1 reference

Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas

31 March 2020

1 reference

A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies

31 March 2020

1 reference

A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma

31 March 2020

1 reference

Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data

31 March 2020

1 reference

Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane.

31 March 2020

1 reference

Estrogen modulation of osteoclast lysosomal enzyme secretion

31 March 2020

1 reference

Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies

31 March 2020

1 reference

Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma

31 March 2020

1 reference

Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours

31 March 2020

1 reference

Designing polymer conjugates as lysosomotropic nanomedicines

31 March 2020

1 reference

Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin

31 March 2020

1 reference

Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer

31 March 2020

1 reference

Intraperitoneal therapy for ovarian cancer: a treatment ready for prime time

31 March 2020

1 reference

Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies

31 March 2020

1 reference

Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models

31 March 2020

1 reference

Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors

31 March 2020

1 reference

Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine

31 March 2020

1 reference

Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA.

31 March 2020

1 reference

Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells

31 March 2020

1 reference

Mechanisms of cancer drug resistance

31 March 2020

1 reference

Multidrug resistance in cancer: role of ATP-dependent transporters

31 March 2020

1 reference

Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer

31 March 2020

1 reference

Pharmacological strategies for overcoming multidrug resistance

31 March 2020

1 reference

Overcoming Multidrug Resistance in Cancer: An Update on the Clinical Strategy of Inhibiting P-Glycoprotein

31 March 2020

1 reference

On the use of ion-pair chromatography to elucidate doxorubicin release mechanism from polyalkylcyanoacrylate nanoparticles at the cellular level

31 March 2020

1 reference

Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles.

31 March 2020

1 reference

Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting

31 March 2020

1 reference

Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor.

31 March 2020

1 reference

Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer

31 March 2020

1 reference

Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome

31 March 2020

1 reference

Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy

31 March 2020

1 reference

Polymer-drug conjugates: recent development in clinical oncology

31 March 2020

1 reference

Poly (amino acid) micelle nanocarriers in preclinical and clinical studies

31 March 2020

1 reference

Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel

31 March 2020

1 reference

Nanoparticle surface charges alter blood-brain barrier integrity and permeability

31 March 2020

1 reference

Toxicity and tissue distribution of magnetic nanoparticles in mice.

31 March 2020

1 reference

Complement activation and protein adsorption by carbon nanotubes

31 March 2020

1 reference

Application of nanotechnology in cancer therapy and imaging

31 March 2020

1 reference

In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags

31 March 2020

1 reference

Therapeutic nanoparticles for drug delivery in cancer

31 March 2020

1 reference

Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice

31 March 2020

1 reference

Clinical pharmacokinetics of topotecan

31 March 2020

1 reference

Targeted anticancer immunotoxins and cytotoxic agents with direct killing moieties.

31 March 2020

1 reference

Ligand-targeted therapeutics in anticancer therapy

31 March 2020

1 reference

Polymer conjugates as anticancer nanomedicines

31 March 2020

1 reference

Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer

31 March 2020

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=18758474

31 March 2020

Identifiers

2 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017

Dimensions Publication ID

1020803706

0 references

1 reference

Consolidated OpenCitations Corpus – April 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=18758474

PubMed publication ID

2 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017